studies

lung cancer : non small cell (NSCLC), durvalumab plus osimertinib vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCAURAL (EXPLORATORY), 2019 2.60 [0.39; 17.16] 2.60[0.39; 17.16]CAURAL (EXPLORATORY), 201910%29NAnot evaluable progression or deaths (PFS)detailed resultsCAURAL (EXPLORATORY), 2019 1.10 [0.22; 5.61] 1.10[0.22; 5.61]CAURAL (EXPLORATORY), 201910%29NAnot evaluable objective responses (ORR)detailed resultsCAURAL (EXPLORATORY), 2019 0.45 [0.08; 2.40] 0.45[0.08; 2.40]CAURAL (EXPLORATORY), 201910%29NAnot evaluable AE (any grade)detailed resultsCAURAL (EXPLORATORY), 2019 1.43 [0.03; 77.69] 1.43[0.03; 77.69]CAURAL (EXPLORATORY), 201910%29NAnot evaluable AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 12.38 [1.29; 118.34] 12.38[1.29; 118.34]CAURAL (EXPLORATORY), 201910%29NAnot evaluable AE leading to death (grade 5)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable SAE (any grade)detailed resultsCAURAL (EXPLORATORY), 2019 1.64 [0.32; 8.45] 1.64[0.32; 8.45]CAURAL (EXPLORATORY), 201910%29NAnot evaluable STRAE (any grade)detailed resultsCAURAL (EXPLORATORY), 2019 0.33 [0.01; 10.81] 0.33[0.01; 10.81]CAURAL (EXPLORATORY), 201910%29NAnot evaluable TRAE (any grade)detailed resultsCAURAL (EXPLORATORY), 2019 2.33 [0.41; 13.17] 2.33[0.41; 13.17]CAURAL (EXPLORATORY), 201910%29NAnot evaluable TRAE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 7.08 [0.34; 148.71] 7.08[0.34; 148.71]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Back pain AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Constipation AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Cough AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 1.44 [0.04; 46.58] 1.44[0.04; 46.58]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Dry skin AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Nausea AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70] 3.07[0.13; 74.70]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 3.07 [0.13; 74.70] 3.07[0.13; 74.70]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Pruritus AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Rash AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsCAURAL (EXPLORATORY), 2019 0.70 [0.01; 37.74] 0.70[0.01; 37.74]CAURAL (EXPLORATORY), 201910%29NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-06-14 22:33 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 1073